Search in:

Expert Opinion on Biological Therapy Volume 16, 2016 - Issue 3

Submit an article Journal homepage

868

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Bevacizumab for the treatment of cervical cancer

Nicolò BizzarriAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Valentina GhirardiAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Franco AlessandriUnit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy

Pier Luigi VenturiniAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Mario Valenzano MenadaAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Stuart RundleNorthern Gynaecological Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK

Umberto Leone Roberti MaggioreAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

Simone FerreroAcademic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, ItalyCorrespondence[email protected] [email protected]

show all

Pages 407-419 | Received 24 Jul 2015, Accepted 19 Jan 2016, Published online: 11 Feb 2016

Cite this article
https://doi.org/10.1517/14712598.2016.1145208
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
Google Scholar
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
PubMed Web of Science ®Google Scholar
Vaccarella S, Lortet-Tieulent J, Plummer M, et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer. 2013;49:3262–3327.
PubMed Web of Science ®Google Scholar
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
PubMed Web of Science ®Google Scholar
Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2004. Bethesda (MD): National Cancer Institute; 2007.
Google Scholar
Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26(35):5802–5812.
PubMed Web of Science ®Google Scholar

• Systematic review and meta-analysis of 18 randomized trials that approved concurrent chemoradiation as standard treatment of LACC.

DiSaia P, Creasman W. Clinical gynecologic oncology. Philadelphia: Mosby; 2012.
Google Scholar
Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103(2):489–493.
PubMed Web of Science ®Google Scholar

•• First study that involves the use of bevacizumab in patients with cervical cancer.

Leone Roberti Maggiore U, Bellati F, Ruscito I, et al. Monoclonal antibodies therapies for ovarian cancer. Expert Opin Biol Ther. 2013;13:739–764.
PubMed Web of Science ®Google Scholar

• A very complete overview of monoclonal antibodies for the treatment of ovarian cancer.

Moreira IS, Fernandes PA, Ramos MJ. Vascular endothelial growth factor (VEGF) inhibition-a critical review. Anticancer Agents Med Chem. 2007;7:223–245.
PubMed Web of Science ®Google Scholar
Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 2000;19(40):4611–4620.
PubMed Web of Science ®Google Scholar
Toussaint-Smith E, Donner DB, Roman A. Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene. 2004;23(17):2988–2995.
PubMed Web of Science ®Google Scholar
Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst. 1995;87(16):1237–1245.
PubMedGoogle Scholar
Kaku T, Hirakawa T, Kamura T, et al. Angiogenesis in adenocarcinoma of the uterine cervix. Cancer. 1998;83(7):1384–1390.
PubMed Web of Science ®Google Scholar
Lenczewski A, Terlikowski S, Famulski W, et al. Angiogenesis as a prognostic factor in invasive carcinoma of the uterine cervix. Folia Histochem Cytobiol. 2001;39(2):165–166.
PubMed Web of Science ®Google Scholar
Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–743.
PubMed Web of Science ®Google Scholar

•• Pivotal phase III trial that demonstrated an improvement in OS by adding bevacizumab to chemotherapy in patients with persistent, recurrent, and metastatic cervical cancer, with subsequent FDA approval for these patients.

Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105(2):107–108.
PubMed Web of Science ®Google Scholar
National Comprehensive Cancer Network. NCC Clinical Practice Guidelines in Oncology: Cervical Cancer Version 2.2015. [ cited 2015 Dec 20]. Available from: http://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf
Google Scholar
Stehman FB, Bundy BN, DiSaia PJ, et al. Carcinoma of the cervix treated with radiation therapy. I. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67:2776–2785.
PubMed Web of Science ®Google Scholar
Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–1143.
PubMed Web of Science ®Google Scholar
Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–1161.
PubMed Web of Science ®Google Scholar
Peters WA, Liu PY, Barrett RGW, et al. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: Report of a Phase III inter group study. Presented at Soc Gynecol Oncol 30th Annual Meeting; 1999 February 5–9; San Fransisco, CA.
Google Scholar
Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:144–153.
PubMed Web of Science ®Google Scholar
Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–1348.
PubMed Web of Science ®Google Scholar
NCI Issues Clinical Announcement on Cervical Cancer: Chemotherapy Plus Radiation Improves Survival. [ cited 2015 Dec 20]. Available from: http://www.nih.gov/news/pr/feb99/nci-22.htm
Google Scholar
Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113–3119.
PubMed Web of Science ®Google Scholar
Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–4655.
PubMed Web of Science ®Google Scholar

•• Important study showing that combination of cisplatin–paclitaxel is superior to other cisplatin doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma.

Grigsby PW. Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer. Radiat Med. 2005;23(5):327–330.
PubMedGoogle Scholar
Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7(10):837–847.
PubMed Web of Science ®Google Scholar
Rutledge S, Carey MS, Prichard H, et al. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol. 1994;52(3):353–359.
PubMed Web of Science ®Google Scholar
Maneo A, Landoni F, Cormio G, et al. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer. 1999;9(4):295–301.
PubMed Web of Science ®Google Scholar
Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:199–303.
PubMed Web of Science ®Google Scholar
Moore DH. Chemotherapy for advanced, recurrent, and metastatic cervical cancer. J Natl Compr Canc Netw. 2008;6:53–57.
PubMedGoogle Scholar
DrugBank: bevacizumab. [ cited 2015 Dec 20]. Available from: http://www.drugbank.ca/drugs/DB00112
Google Scholar
Gerber H-P, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671–680.
PubMed Web of Science ®Google Scholar
Pañares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther. 2007;7:433–445.
PubMed Web of Science ®Google Scholar
Kerbel RS. Tumor angiogenesis. N Eng J Med. 2008;358:2335–2342.
Web of Science ®Google Scholar
Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507.
PubMed Web of Science ®Google Scholar
Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779–786.
PubMed Web of Science ®Google Scholar
Avastin 25mg/ml concentrate for solution for infusion. [ cited 2015 Dec 20]. Available from: https://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/#PHARMACOKINETIC_PROPS
Google Scholar
Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779–1802.
PubMed Web of Science ®Google Scholar
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
PubMed Web of Science ®Google Scholar
Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2:795–803.
PubMed Web of Science ®Google Scholar
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027.
PubMed Web of Science ®Google Scholar
Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777–794.
PubMed Web of Science ®Google Scholar
Stafl A, Matinngly RF. Angiogenesis of cervical neoplasia. Am J Obstet Gynecol. 1975;121(6):845–852.
PubMed Web of Science ®Google Scholar

• One of the first studies on the role of angiogenesis in cervical cancer.

Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 2003;9(6):2234–2240.
PubMed Web of Science ®Google Scholar
Cheng WF, Chen CA, Lee CN, et al. Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000;96:721–726.
PubMed Web of Science ®Google Scholar
Loncaster JA, Cooper RA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000;83(5):620–625.
PubMed Web of Science ®Google Scholar
Lee IJ, Park KR, Lee KK, et al. Prognostic value of vascular endothelial growth factor in Stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 2002;54(3):768–779.
PubMed Web of Science ®Google Scholar

• Significant study that evaluates the prognostic value of VEGF in cervical cancer.

Silva-Filho AL, Traiman P, Triginelli SA, et al. Association between CD31 expression and histopathologic features in stage IB squamous cell carcinoma of the cervix. Int J Gynecol Cancer. 2006;16(2):757–762.
PubMed Web of Science ®Google Scholar
Randall LM, Monk BJ, Darcy KM, et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2009;112(3):583–589.
PubMed Web of Science ®Google Scholar
Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27(7):1069–1074.
PubMed Web of Science ®Google Scholar

•• Prominent phase II trial of bevacizumab in combination with other drugs in persistent or recurrent cervical cancer.

Zighelboim I, Wright JD, Gao F, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol. 2013;130(1):64–68.
PubMed Web of Science ®Google Scholar

•• Multicenter phase II trial of combination bevacizumab and other drugs in patients with persistent or recurrent cervical cancer.

Penson RT, Huang HQ, Wenzel LB, et al. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015;16(3):301–311.
PubMed Web of Science ®Google Scholar
Phippen NT, Leath CA, Havrilesky LJ, et al. Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective? Gynecol Oncol. 2015;136:43–47.
PubMed Web of Science ®Google Scholar
Minion LE, Bai J, Monk BJ, et al. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer. Gynecol Oncol. 2015;137(3):490–496.
PubMed Web of Science ®Google Scholar
Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116(1):44–49.
PubMed Web of Science ®Google Scholar
Tewari KS, Sill MW, Monk BJ, et al. Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. Clin Cancer Res. 2015;21(24):5480–5487.
PubMed Web of Science ®Google Scholar
Schefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83(4):1179–1184.
PubMed Web of Science ®Google Scholar

•• The only phase II trial evaluating safety of the addition of bevacizumab to standard chemoradiation in LACC (1st part).

Schefter T, Winter K, Kwon JS, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapyin untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014;88(1):101–105.
PubMed Web of Science ®Google Scholar

•• The only phase II trial evaluating efficacy of the addition of bevacizumab to standard chemoradiation in LACC (2nd part).

Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004;22(5):872–880.
PubMed Web of Science ®Google Scholar
FDA Approval for Bevacizumab. [ cited 2015 Dec 20]. Available from: http://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab
Google Scholar
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
PubMed Web of Science ®Google Scholar
Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with FOLFOX4 for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544.
PubMed Web of Science ®Google Scholar
Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin alone or with Bevacizumab for NSCLC. N Engl J Med. 2006;355(24):2542–2550.
PubMed Web of Science ®Google Scholar
Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing Bevacizumab plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel alone in previously untreated locally advanced or metastatic NSCLC. J Clin Oncol. 2004;22(11):2184–2191.
PubMed Web of Science ®Google Scholar
Field KM, Jordan JT, Wen PY, et al. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015;121(7):997–1007.
PubMed Web of Science ®Google Scholar
Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–2111.
PubMed Web of Science ®Google Scholar
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–1308.
PubMed Web of Science ®Google Scholar
Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(1):249–257.
PubMed Web of Science ®Google Scholar
Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. Clin Colorectal Cancer. 2011;10(3):151–156.
PubMed Web of Science ®Google Scholar

• Algorithm for the management of bevacizumab-induced hypertension.

Lambrechts D, Moisse M, Delmar P, et al. Genetic markers of bevacizumab-induced hypertension. Angiogenesis. 2014;17(3):685–694.
PubMed Web of Science ®Google Scholar
Tahover E, Uziely B, Salah A, et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol. 2013;30(1):327.
PubMed Web of Science ®Google Scholar
Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20(2):227–230.
PubMed Web of Science ®Google Scholar
Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23(5):460–468.
PubMed Web of Science ®Google Scholar

• Meta-analysis on bevacizumab-induced hypertension.

Krill LS, Adelson JW, Randall LM, et al. Clinical commentary: medical ethics and the ramifications of equipoise in clinical research. Is a confirmatory trial using a nonbevacizumab containing arm feasible in patients with recurrent cervical cancer? Gynecol Oncol. 2014;134(3):447–449.
PubMed Web of Science ®Google Scholar
Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027–4034.
PubMed Web of Science ®Google Scholar
Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014;20(17):4549–4558.
PubMed Web of Science ®Google Scholar
Hansen TF, Nielsen BS, Sørensen FB, et al. Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer. Mol Cancer Ther. 2014;13(9):2238–2245.
PubMed Web of Science ®Google Scholar
Hansen TF, Carlsen AL, Heegaard NH, et al. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer. Br J Cancer. 2015;112(4):624–629.
PubMed Web of Science ®Google Scholar
Weickhardt AJ, Williams DS, Lee CK, et al. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer. 2015;113(1):37–45.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bevacizumab for the treatment of cervical cancer

References

• Systematic review and meta-analysis of 18 randomized trials that approved concurrent chemoradiation as standard treatment of LACC.

•• First study that involves the use of bevacizumab in patients with cervical cancer.

• A very complete overview of monoclonal antibodies for the treatment of ovarian cancer.

•• Pivotal phase III trial that demonstrated an improvement in OS by adding bevacizumab to chemotherapy in patients with persistent, recurrent, and metastatic cervical cancer, with subsequent FDA approval for these patients.

•• Important study showing that combination of cisplatin–paclitaxel is superior to other cisplatin doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma.

• One of the first studies on the role of angiogenesis in cervical cancer.

• Significant study that evaluates the prognostic value of VEGF in cervical cancer.

•• Prominent phase II trial of bevacizumab in combination with other drugs in persistent or recurrent cervical cancer.

•• Multicenter phase II trial of combination bevacizumab and other drugs in patients with persistent or recurrent cervical cancer.

•• The only phase II trial evaluating safety of the addition of bevacizumab to standard chemoradiation in LACC (1st part).

•• The only phase II trial evaluating efficacy of the addition of bevacizumab to standard chemoradiation in LACC (2nd part).

• Algorithm for the management of bevacizumab-induced hypertension.

• Meta-analysis on bevacizumab-induced hypertension.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bevacizumab for the treatment of cervical cancer

References

• Systematic review and meta-analysis of 18 randomized trials that approved concurrent chemoradiation as standard treatment of LACC.

•• First study that involves the use of bevacizumab in patients with cervical cancer.

• A very complete overview of monoclonal antibodies for the treatment of ovarian cancer.

•• Pivotal phase III trial that demonstrated an improvement in OS by adding bevacizumab to chemotherapy in patients with persistent, recurrent, and metastatic cervical cancer, with subsequent FDA approval for these patients.

•• Important study showing that combination of cisplatin–paclitaxel is superior to other cisplatin doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma.

• One of the first studies on the role of angiogenesis in cervical cancer.

• Significant study that evaluates the prognostic value of VEGF in cervical cancer.

•• Prominent phase II trial of bevacizumab in combination with other drugs in persistent or recurrent cervical cancer.

•• Multicenter phase II trial of combination bevacizumab and other drugs in patients with persistent or recurrent cervical cancer.

•• The only phase II trial evaluating safety of the addition of bevacizumab to standard chemoradiation in LACC (1st part).

•• The only phase II trial evaluating efficacy of the addition of bevacizumab to standard chemoradiation in LACC (2nd part).

• Algorithm for the management of bevacizumab-induced hypertension.

• Meta-analysis on bevacizumab-induced hypertension.

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date